RATIONALE: Delineation of the receptor mechanisms underlying the behavioral effects of benzodiazepines should allow for the development of drugs with improved clinical utility and reduced side effects. OBJECTIVES. The purpose of the present study was to investigate the role of GABAA/alpha1 receptors in the sedative and motor-impairing effects of benzodiazepines. METHODS: Squirrel monkeys were tested with the GABAA/alpha1-preferring agonist zolpidem and the nonselective benzodiazepine agonist triazolam alone and in combination with the GABAA/alpha1-preferring antagonist beta-CCt and the nonselective benzodiazepine antagonist flumazenil. During 30-min experimental sessions, all occurrences of normal behaviors like locomotion, environment- and self-directed behaviors, as well as side effects such as ataxia, rest and procumbent postures were scored. RESULTS: Zolpidem and triazolam produced dose-dependent reductions in locomotion and environment-directed behavior and increased ataxia and procumbent posture. Triazolam, but not zolpidem, also engendered species-typical rest posture at some doses. Flumazenil antagonized all of the behavioral effects of zolpidem and triazolam, whereas beta-CCt antagonized only zolpidem- and triazolam-induced ataxia. CONCLUSIONS: GABAA/alpha1 receptor mechanisms appear to play a key role in the ataxic effects of benzodiazepine agonists in squirrel monkeys, similar to recent results with transgenic mice. In contrast to the findings of these recent studies, GABAA mechanisms other than or in addition to those mediated at the alpha1 subunit may play a more important role in the sedative/hypnotic effects of benzodiazepines in squirrel monkeys.
RATIONALE: Delineation of the receptor mechanisms underlying the behavioral effects of benzodiazepines should allow for the development of drugs with improved clinical utility and reduced side effects. OBJECTIVES. The purpose of the present study was to investigate the role of GABAA/alpha1 receptors in the sedative and motor-impairing effects of benzodiazepines. METHODS: Squirrel monkeys were tested with the GABAA/alpha1-preferring agonist zolpidem and the nonselective benzodiazepine agonist triazolam alone and in combination with the GABAA/alpha1-preferring antagonist beta-CCt and the nonselective benzodiazepine antagonist flumazenil. During 30-min experimental sessions, all occurrences of normal behaviors like locomotion, environment- and self-directed behaviors, as well as side effects such as ataxia, rest and procumbent postures were scored. RESULTS:Zolpidem and triazolam produced dose-dependent reductions in locomotion and environment-directed behavior and increased ataxia and procumbent posture. Triazolam, but not zolpidem, also engendered species-typical rest posture at some doses. Flumazenil antagonized all of the behavioral effects of zolpidem and triazolam, whereas beta-CCt antagonized only zolpidem- and triazolam-induced ataxia. CONCLUSIONS:GABAA/alpha1 receptor mechanisms appear to play a key role in the ataxic effects of benzodiazepine agonists in squirrel monkeys, similar to recent results with transgenic mice. In contrast to the findings of these recent studies, GABAA mechanisms other than or in addition to those mediated at the alpha1 subunit may play a more important role in the sedative/hypnotic effects of benzodiazepines in squirrel monkeys.
Authors: Eileen K Sawyer; Casey Moran; Madelynn H Sirbu; Melissa Szafir; Michael Van Linn; Ojas Namjoshi; V V N Phani Babu Tiruveedhula; James M Cook; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2013-12-13 Impact factor: 3.455
Authors: Angela N Duke; Donna M Platt; James M Cook; Shengming Huang; Wenyuan Yin; Bruce A Mattingly; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2006-06-17 Impact factor: 4.530
Authors: Bradford D Fischer; John R Atack; Donna M Platt; David S Reynolds; Gerard R Dawson; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2010-12-30 Impact factor: 4.530
Authors: Angela N Duke; Zhiqiang Meng; Donna M Platt; John R Atack; Gerard R Dawson; David S Reynolds; V V N Phani Babu Tiruveedhula; Guanguan Li; Michael Rajesh Stephen; Werner Sieghart; James M Cook; James K Rowlett Journal: J Pharmacol Exp Ther Date: 2018-05-02 Impact factor: 4.030
Authors: Srđan Joksimović; Zdravko Varagic; Jovana Kovačević; Michael Van Linn; Marija Milić; Sundari Rallapalli; Tamara Timić; Werner Sieghart; James M Cook; Miroslav M Savić Journal: Psychopharmacology (Berl) Date: 2013-05-18 Impact factor: 4.530
Authors: Dongmei Han; F Holger Försterling; Xiaoyan Li; Jeffrey R Deschamps; Damon Parrish; Hui Cao; Sundari Rallapalli; Terry Clayton; Yun Teng; Samarpan Majumder; Subramaniam Sankar; Bryan L Roth; Werner Sieghart; Roman Furtmuller; James K Rowlett; Michael R Weed; James M Cook Journal: Bioorg Med Chem Date: 2008-09-02 Impact factor: 3.641
Authors: Daniela Rüedi-Bettschen; James K Rowlett; Sundari Rallapalli; Terry Clayton; James M Cook; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2012-11-05 Impact factor: 3.455
Authors: Stephanie C Licata; Donna M Platt; James M Cook; Michael L Van Linn; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2008-11-25 Impact factor: 4.530